Evidence map›Paper›PMID 29444091›Full record

SynthesisPloS one2018

A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker.

Chenkai Ma, Hong P T Nguyen, Rodney B Luwor, Stanley S Stylli, Andrew Gogos, Lucia Paradiso, Andrew H Kaye, Andrew P Morokoff

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 5 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 5 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. A Synopsis of Biomarkers in Glioblastoma: Past and Present.Current issues in molecular biology · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Molecular and Circulating Biomarkers in Patients with Glioblastoma.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chenkai MaDepartment of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Hong P T NguyenDepartment of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Rodney B LuworDepartment of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Stanley S StylliDepartment of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Andrew GogosDepartment of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Lucia ParadisoDepartment of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Andrew H KayeDepartment of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Andrew P MorokoffDepartment of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria, Australia.ORCID 0000-0002-5159-3438
The Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is the most common malignant intracranial tumour. Recently, several publications have suggested that miRNAs can be used as potential diagnostic biomarkers of glioma. Here we performed a meta-analysis to identify the diagnostic accuracy of differentially expressed circulating miRNAs in gliomas. Using PubMed, Medline and Cochrane databases, we searched for studies which evaluated a single or panel of miRNAs from circulating blood as potential biomarkers of glioma. Sixteen publications involving 23 studies of miRNAs from serum or plasma met our criteria and were included in this meta-analysis. The pooled diagnostic parameters were calculated by random effect models and overall diagnostic performance of altered miRNAs was illustrated by the summary receiver operator characteristic (SROC) curves. The pooled sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR) from each study were calculated. The pooled PLR, NLR and Diagnostic Odds Ratio were 6.39 (95% CI, 4.61-8.87), 0.15 (95% CI, 0.11-0.21) and 41.91 (95% CI, 23.15-75.88), respectively. The pooled sensitivity, specificity and area under the curve (AUC) were 0.87 (95% CI, 0.82-0.91), 0.86 (95% CI, 0.82-0.90) and 0.93 (95% CI, 0.91-0.95), respectively. This meta-analysis demonstrated that circulating miRNAs are capable of distinguishing glioma from healthy controls. Circulating miRNAs are promising diagnostic biomarkers for glioma and can potentially be used as a non-invasive early detection.

Indexed as

BiomarkersBrain NeoplasmsGliomaHumansMicroRNAsBiomarkersMicroRNAs

Identifiers

PMID29444091
PMCPMC5812551
OpenAlexW2793963805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.